Core Viewpoint - The company, Weiston, has announced the extension of the implementation deadlines for all three of its fundraising projects due to a decline in both revenue and net profit, aiming to ensure the quality and commercial value of the projects [1][6]. Group 1: Project Deadline Extensions - The "Intelligent MES System Optimization Project" deadline has been extended to December 31, 2028, from February 28, 2026 [1]. - The "Quality Traceability and Analysis System Optimization Project" deadline has been extended to December 31, 2027, from August 31, 2025 [4]. - The "Big Data Platform Management Portal Product R&D Project" deadline has been extended to December 31, 2026, from January 31, 2025 [5][6]. Group 2: Financial Performance - In 2024, the company reported a total revenue of 294 million, a year-on-year decrease of 6.32%, and a net profit of 51.71 million, down 11.26% [6]. - For the first three quarters of 2025, the company achieved a revenue of 122 million, a decline of 32.34%, and a net profit of 21.49 million, down 28.30% [6]. Group 3: Fundraising and Investment - The total amount raised from the IPO in 2023 was approximately 710 million, with a net amount of about 615 million after deducting issuance costs [2]. - As of November 30, 2025, the cumulative investment in fundraising projects amounted to 98.12 million [2][3].

Core Viewpoint - The company announced a postponement of the "smart MES system optimization project based on industrial internet architecture" to December 31, 2028, without requiring shareholder approval [1] Financial Summary - As of November 30, 2025, the total investment in the fundraising project reached 98.1183 million yuan, with 74.5731 million yuan specifically allocated to this project [1] Reasons for Delay - The delay is attributed to the unexpected complexity of AI technology integration, deepening market demand, and the need for product refinement and validation [1] Impact on Operations - The postponement does not constitute a substantial change to the fundraising project and is not expected to have a significant adverse impact on the company's operations [1]